A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses - PubMed (original) (raw)
A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses
Frank Neumann et al. Cancer Immunol Immunother. 2011 Sep.
Abstract
Background: Antigen-derived HLA class I-restricted peptides can generate specific CD8(+) T-cell responses in vivo and are therefore often used as vaccines for patients with cancer. However, only occasional objective clinical responses have been reported suggesting the necessity of CD4(+) T-cell help and possibly antibodies for the induction of an effective anti-tumor immunity in vivo. The SSX2 gene encodes the cancer testis antigen (CTA) HOM-MEL-40/SSX2, which is frequently expressed in a wide spectrum of cancers. Both humoral and cellular immune responses against SSX2 have been described making SSX2 an attractive candidate for vaccine trials.
Methods: SYFPEITHI algorithm was used to predict five pentadecamer peptides with a high binding probability for six selected HLA-DRB1 subtypes (*0101, *0301, *0401, *0701, *1101, *1501) which are prevalent in the Caucasian population.
Results: Using peripheral blood cells of 13 cancer patients and 5 healthy controls, the HOM-MEL-40/SSX2-derived peptide p101-111 was identified as an epitope with dual immunogenicity for both CD4(+) helper and cytotoxic CD8(+) T cells. This epitope also reacted with anti-SSX2 antibodies in the serum of a patient with breast cancer. Most remarkably, SSX2/p101-111 simultaneously induced specific CD8, CD4, and antibody responses in vitro.
Conclusions: p101-111 is the first CTA-derived peptide which induces CD4(+), CD8(+), and B-cell responses in vitro. This triple-immunogenic peptide represents an attractive vaccine candidate for the induction of effective anti-tumor immunity.
Figures
Fig. 1
CD4+ T-cell responses against HOM-MEL-40/SSX2-derived peptides and characterization of the CD4+ effector T cells. T cells from patients BC399 (a) and BC418 (b) responded after priming with the peptide pool to challenge with both p98-112 and p101-15. The response of T-cells from both patients against both peptides was blocked by anti-HLA-DR, but not by anti-HLA-DP. T cells from patient BC418 were also blocked by anti-CD4. c Response of bulk T cells from patient BC399 using single peptide p98-112 or p101-115. Filled bars represent the IFN-γ response of p98-112 primed bulk T cells when challenged with p98-112 (P = 0.003) and p101-115 (P < 0.02), respectively. Empty bars represent the response of T cells primed with p101-115 and challenged with p98-112 (P < 0.007) and p101-115 (P = 0.04), respectively. Y axes display the different APC settings used to challenge T cells during IFN-γ ELISPOT. d During stimulation with peptide p101-115 (patient BC399) and p98-112 (patient BC418), respectively, effector memory T cells of both patients increased considerably. CD4+ T cells of clone #10 all belong to the effector memory type
Fig. 2
Dissection of the HLA-DR restriction of the T-cell response against SSX2-derived peptides p98-112 and p101-115 and natural processing and presentation of epitope p98-112. a Restriction of the T-cell response against p98-112 and p101-115 using the melanoma cell line SK-MEL-37 as APC. This cell line shares only DRB1*0101 with the BC399-derived T cells from line #98 and #101. DR restriction was demonstrated by blocking the response of both T-cell lines against APC pre-incubated with the anti-DR antibody clone L243. b DRB1*0701 restriction of the response from T cells of the BC399-lines #98 and #101 against LCL Co89 pulsed with peptide p101-115. *0701 is the only DRB1 subtype shared by Co89 and patient BC399. c Dissection of the restriction of the T-cell response of clone #10 from patient BC418: a response after stimulation with p98-112 or p101-115 only was observed when these peptides were presented by LCL from BC399 and AlaBM (P < 0.01) proving the restriction of these T cells to HLA-DRB1*0101, which is the only DR molecule shared by effector cells and APC. There was no response if both peptides were presented on LCL from PC 1, Co89, or Co125 excluding a restriction to HLA-DRB1*0301 or DRB3*0202. _Y_-axes of the A, B, and C panels display the different APC settings used to challenge T cells during IFN-γ ELISPOT. d Loading of autologous DC (1 × 104/well) with increasing concentrations of SSX2 whole protein induced a concentration-dependent response of clone #10 CD4+ T cells, which was blocked by anti-HLA-DR. The control antigen (SCP1 fragment p630-817) was not recognized (P < 0.001). Y axis shows the different DC settings used to challenge T cells during IFN-γ ELISPOT
Fig. 3
Determination of peptide p101-111 as immunogenic core of the two peptides p98-112 and p101-115 and demonstration of the cytotoxic T-cell response against the core epitope p101-111. a After priming with peptide p98-112 CD4+ T cells of clone #10 (BC418) responded equally in IFN-γ ELISPOT when challenged with the pentadecamers p98-112 and p101-115 (P < 0.001) presented by allogeneic APC (3 × 104 LCL BC399/well). Peptide p101-111 was the only undecamer peptide to induce a response by clone #10 T cells (P < 0.001). Y axis displays the different APC settings used during IFN-γ ELISPOT. b HLA-A*0201-restricted CD8+ T cells from clone #24, which were generated by in vitro priming with the SSX2-derived nonamer p103-111, were used as effector cells in a CR51 release assay against HLA-A*0201+ T2 cells pulsed with decreasing concentrations of peptide p101-111 (triangles) or p103-111 (squares) by an E/T ratio of 10:1. Specific lysis of peptide-pulsed targets induced by clone #24 CD8+ T cells demonstrated a strong and dose-dependent cytotoxic T-cell response in an HLA-A*0201-restricted way. In contrast, the CTL epitope p41-49 (diamonds/dashed line), also derived from SSX2, as well as the DRB1*0101-restricted pentadecamer p98-112 (empty circles/spotted line) did not cause any cytotoxicity in the context of HLA-A*0201. c Further evidence for the HLA-A*0201 restriction of the CD8+ T cells after SSX2/p101-111 stimulation was shown by displacing an HLA-A*0201 reference peptide out of its MHC molecules, leading to modified antigen presenting functions of the APC and to a different induction pattern for T-cell responses finally. Increasing concentrations of the triple epitope resulted in a decreasing response of the HLA-A*0201-restricted IMP-specific clone #46 (diamonds/dashed line) and in a similarly increasing activity of the SSX2/p101-111 specific clone #9 (triangles/continuous line). Read out by ELISPOT against T2 cells pulsed with 0.1 μg/ml of the A*0201 reference peptide IMP/p58-66 either alone (1st concentration) or concurrently with increasing concentrations of SSX2/p101-111 (2nd-7th concentration). Both clones were run in separate experiments using T2 cells prepared in the same way
Fig. 4
Simultaneous induction of a response by T-helper cells and by cytotoxic T cells as well as antibody production after in vitro stimulation with the SSX2-derived epitope p101-111. a After 35 days of in vitro stimulation of PBMC derived from patient BC699 with p101-111, the supernatant was analyzed by ELISA for antibodies binding to recombinantly expressed SSX2 fragments spanning the amino acids sequences as indicated on the X axis. This supernatant contained antibodies binding concentration dependent to SSX2 101-110 (empty [1:5-diluted] and gray [1:10-diluted] bars) and showed the same binding pattern (P < 0.01) as the positive serum derived from a melanoma cancer patient (black bars). At the beginning of the stimulation, such antibodies had not been present (horizontal stripes). A parallel stimulation using CMV-derived control peptides did not induce antibodies with affinity to any of the SSX2 fragments (striped bars [1:10]). SSX2− control serum also induced no significant ELISA signals (checkered bars). Only antibodies of the IgG class were analyzed. b PBMC from the HLA-A*0201, HLA-DRB1*0101 patient BC699 who had an SSX2-expressing tumor, were stimulated in vitro for 28 days with the epitope p101-111. The bulk lymphocytes developed simultaneously a strong T-cell response mediated by CD4+ T-helper cells as wells as by CD8+ cytotoxic T cells as shown by IFN-γ- release in the ELISPOT assay. Empty bars represent the response of 2.5 × 104 CD4+ bulk T cells/well against autologous PBMC (5 × 104/well) pulsed and labeled with the indicated peptide (4 μg/ml) and antibodies, respectively. Black bars represent the response of 2.5 × 104 CD8+ bulk T cells/well against T2 cells (3 × 104/well) pulsed and labeled with the indicated peptide (4 μg/ml) and antibodies, respectively. Y axis shows the different APC conformations. c After 35 days of in vitro stimulation with the undecamer peptide p101-111, the CD8+ T-cell fraction of the bulk culture of BC699 had developed a strong cytotoxic activity as assessed by LDH release assay. Lysis of cells of the HLA-A*0201+ and SSX2+ melanoma cell line SK-MEL-37 without external peptide pulsing demonstrated that epitope p101-111 is processed and presented via the MHC-I pathway. The HLA-A*0201+, but SSX2− line BT 549 caused lysis only after external pulsing with this peptide. Y axis displays the different APC conformations
Similar articles
- Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M. Neumann F, et al. Int J Cancer. 2004 Nov 20;112(4):661-8. doi: 10.1002/ijc.20461. Int J Cancer. 2004. PMID: 15382048 - Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M. Wagner C, et al. Cancer Immun. 2003 Dec 17;3:18. Cancer Immun. 2003. PMID: 14677925 - DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.
Smith HA, Rekoske BT, McNeel DG. Smith HA, et al. Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. Epub 2014 Jan 31. Vaccine. 2014. PMID: 24492013 Free PMC article. - Deciphering CD4+ T cell-mediated responses against cancer.
Kirkpatrick C, Lu YW. Kirkpatrick C, et al. Mol Carcinog. 2024 Jul;63(7):1209-1220. doi: 10.1002/mc.23730. Epub 2024 May 9. Mol Carcinog. 2024. PMID: 38725218 Review. - Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Martinenaite E, Ahmad SM, Bendtsen SK, Jørgensen MA, Weis-Banke SE, Svane IM, Andersen MH. Martinenaite E, et al. Cancer Immunol Immunother. 2019 Nov;68(11):1901-1907. doi: 10.1007/s00262-019-02425-6. Epub 2019 Nov 6. Cancer Immunol Immunother. 2019. PMID: 31690955 Free PMC article. Review.
Cited by
- Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review).
Ren S, Zhang Z, Li M, Wang D, Guo R, Fang X, Chen F. Ren S, et al. Int J Oncol. 2023 Jun;62(6):71. doi: 10.3892/ijo.2023.5519. Epub 2023 May 5. Int J Oncol. 2023. PMID: 37144487 Free PMC article. Review. - Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Protective Effect of Alkaline Phosphatase Supplementation on Infant Health.
Wu H, Wang Y, Li H, Meng L, Zheng N, Wang J. Wu H, et al. Foods. 2022 Apr 21;11(9):1212. doi: 10.3390/foods11091212. Foods. 2022. PMID: 35563935 Free PMC article. Review. - Cancer testis antigens as immunogenic and oncogenic targets in breast cancer.
Mahmoud AM. Mahmoud AM. Immunotherapy. 2018 Jul;10(9):769-778. doi: 10.2217/imt-2017-0179. Epub 2018 Jun 21. Immunotherapy. 2018. PMID: 29926750 Free PMC article. Review. - Localization of CD8 T cell epitope within cardiac myosin heavy chain-α334-352 that induces autoimmune myocarditis in A/J mice.
Massilamany C, Gangaplara A, Basavalingappa RH, Rajasekaran RA, Khalilzad-Sharghi V, Han Z, Othman S, Steffen D, Reddy J. Massilamany C, et al. Int J Cardiol. 2016 Jan 1;202:311-21. doi: 10.1016/j.ijcard.2015.09.016. Epub 2015 Sep 18. Int J Cardiol. 2016. PMID: 26422020 Free PMC article.
References
- Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000;60:6272–6275. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials